華美萍
[摘要] 目的 探討經(jīng)陰道彩色多普勒超聲測定血流速度、阻力指數(shù)對卵巢癌新輔助化療效果的評估價值。方法 方便選取2016年1月—2017年6月該院收治的63例新輔助化療卵巢癌患者為研究對象。化療前后,以陰式彩超測量原發(fā)灶體積、血流速度及阻力指數(shù),評估化療效果。觀察經(jīng)陰彩超評估新輔助化療效果的敏感度、特異度及符合率。結(jié)果 陰式彩超化療后測定原發(fā)灶體積(240.57±93.64)cm3、Vmax(3.12±0.75)cm/s、RI(0.71±0.06),對化療前比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。陰式彩超評價化療靈敏度92.73%,特異度87.50%,符合率92.06%。結(jié)論 陰式彩超是評價卵巢癌新輔助化療效果的有效手段,測定血流速度和阻力指數(shù)能夠較好的根據(jù)血流變化掌握病灶對化療的反應(yīng),對治療方案的及時調(diào)整具有積極作用,值得推廣使用。
[關(guān)鍵詞] 卵巢癌;新輔助化療;經(jīng)陰彩色多普勒超聲;血流速度;阻力指數(shù)
[中圖分類號] R445 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1674-0742(2017)11(a)-0188-03
[Abstract] Objective To study the value of trans-vaginal color Doppler ultrasound in measuring the blood flow rate and resistance index in evaluating the oophoroma neoadjuvant chemotherapy effect. Methods 63 cases of patients with neoadjuvant chemotherapy in our hospital from January 2016 to June 2017 were convenient selected and the chemotherapy effect was evaluated according to the measurement values of primary lesion volume, blood flow rate and resistance index before and after chemotherapy, and the sensitivity, specificity and coincidence rate were evaluated. Results After chemotherapy, the measurement value of primary lesion, Vmax and RI by the trans-vaginal color Doppler ultrasound were respectively (240.57±93.64)cm3, (3.12±0.75)cm/s and (0.71±0.06), and the differences were statistically significant(P<0.05), and the sensitivity, specificity and coincidence rate of chemotherapy evaluated by trans-vaginal color Doppler ultrasound were respectively 92.73%, 87.50% and 92.06%. Conclusion The trans-vaginal color Doppler ultrasound is an effective means of evaluating the oophoroma neoadjuvant chemotherapy, and it has a positive effect on the timely adjustment of treatment plan, and it is worth promotion and application.
[Key words] Oophoroma; Neoadjuvant chemotherapy; Trans-vaginal color doppler ultrasound; Blood follow rate; Resistance index
卵巢癌是女性生殖系統(tǒng)常見惡性腫瘤,流行病學(xué)統(tǒng)計(jì)我國女性人群發(fā)病率23/10萬~47/10萬,居?jì)D科腫瘤第二位,死亡率居首位,對女性生命健康威脅極大[1]。手術(shù)是現(xiàn)階段臨床治療卵巢癌的首選方法,但由于卵巢癌缺乏特異性,多數(shù)患者于中晚期確診,已錯過最佳治療時機(jī),故手術(shù)效果欠理想[2]。新輔助化療是指為縮小腫塊、殺滅轉(zhuǎn)移細(xì)胞而于手術(shù)或放療前進(jìn)行的全身化療,對提高腫瘤局部治療效果具有促進(jìn)作用。近年來,陰式彩超在新輔助化療效果監(jiān)測中的作用日漸受到關(guān)注,文章現(xiàn)以2016年1月—2017年6月該院63例卵巢癌患者為例,對陰式彩超測定最大血流速度(Vmax)和阻力指數(shù)(RI)評估新輔助化療的效果進(jìn)行行分析和探討,具體報(bào)道如下。
1 資料與方法
1.1 一般資料
方便選取該院收治的63例卵巢癌患者為研究對象。納入標(biāo)準(zhǔn):①病理診斷證實(shí)為卵巢癌;②首次治療;……